Global Bronchopulmonary Dysplasia Market Size, Trend & Opportunity Analysis Report, by Treatment Type (Oxygen Therapy, Mechanical Ventilation, Surfactant Therapy, Medications, and Others), End-User (Hospitals, Speciality Clinics, Ambulatory Surgical Centres, and Others), Age Group (Preterm Infants, Full-term Infants), and Forecast 2025-2035
Global Bronchopulmonary Dysplasia Market Size & Opportunity Analysis & Forecast, 2025-2035
Market Definition and Introduction
The Global Bronchopulmonary Dysplasia Market is expected to grow significantly, with its value estimated at around USD 1.39 billion in 2025 and projected to reach USD 2.86 billion by 2035. This growth reflects a robust CAGR of 7.5% during the forecast period 2025 - 2035. Key factors fuelling this expansion include the rising number of preterm births and ongoing advancements in neonatal care technologies. The bronchopulmonary dysplasia market is very specific.
At its core, the global bronchopulmonary dysplasia market is all about helping premature babies who struggle with serious lung problems. BPD mostly affects infants born too early, before their lungs have had the chance to fully develop. That is why catching it early and starting treatment quickly is so important. Right now, the main treatments include things like bronchodilators and extra oxygen, which can make breathing easier and support lung growth in these tiny patients.
But that is not all. Newer approaches like surfactant therapy and better ventilation methods are starting to bring hope for better outcomes. The market also includes special medical equipment and neonatal care services built to improve survival rates and help these babies live better, healthier lives. It-s not just about care; it is about giving families a real chance to see their children thrive.
Recent Developments in the Industry
- In December 2024, Oak Hill Bio started a clinical trial for OHB-607, a new investigational drug aimed at treating conditions like bronchopulmonary dysplasia in premature babies. There are no approved treatments for this moment, so his study marks a specific step toward filling that gap.
- In April 2021, the FDA approved Airway Therapeutics to move forward with its IND application for AT-100. This treatment is being developed as a preventive option for BPD in weak newborns and brings a novel approach to addressing the condition.
Market Dynamics
Changing Trends in the BPD Market Point to New Avenues for Therapeutic Innovation
The bronchopulmonary dysplasia market appears to be on the verge of meaningful change. One of the main reasons for this shift is the noticeable lack of approved therapies. While this poses challenges, it also creates space for innovative treatments like OHB-607 to step forward and potentially claim a strong market position. As research continues to advance and technology improves, experts are beginning to gain a clearer understanding of its complex nature. This deeper insight is opening the door to more targeted and potentially effective treatment options.Nevertheless, progress will not occur overnight. There is still a pressing need for well-structured clinical studies with clearly defined outcomes. Developing safe and reliable therapies will depend on refining current models so they better reflect how BPD develops in premature infants. With continued research, stronger collaboration, and steady investment, there is real hope that innovation in this area could lead to better outcomes for the most vulnerable newborns.
Key Obstacles Impacting the Development and Expansion of the Bronchopulmonary Dysplasia Therapy Market
The bronchopulmonary dysplasia market holds hope, but some challenges continue to slow its growth. A big problem is the large number of undiagnosed or unreported cases, which is due to limited awareness about the condition, especially in regions with less access to neonatal care. Even with progress in neonatal intensive care, predicting which premature infants will develop BPD is a significant hurdle for clinicians. This makes early intervention more difficult and adds complexity to managing the disease. Another problem lies in the inconsistent definitions and diagnostic criteria used across studies, which makes it difficult to accurately estimate how many infants are right affected by BPD. This variability creates uncertainty in data, presenting a clear risk to market forecasting and planning. Addressing these challenges will be essential to unlock the full potential of the BPD market and ensure good results for weak newborns.
Attractive Opportunities in the Market
- Based on advances in personalised medicine, researchers are opening the way to tailored BOD treatment to individual genetic profiles.
- Improving the result can be helped by targeted therapies and reducing side effects, which makes care safer and more effective for each patient.
- AI and machine learning tools are very important and both help to easily.
- Growing focus on early intervention allows for faster diagnosis and treatment, improving long-term results in preterm infants.
- Educational initiatives for parents and providers help growth awareness of early BPD signs, possibly a timely medical response.
- it can be reduced to BPD cases with the help of Preventive strategies, such as antenatal steroids and maternal health programs and increasing the market growth.
Report Segmentation
By Treatment Type: Oxygen Therapy, Mechanical Ventilation, Surfactant Therapy, Medications, and Others
By End Use: Hospitals, Speciality Clinics, Ambulatory Surgical Centres, and Others
By Age Group: Preterm Infants, Full-term Infants
By Region: North America (U.S, Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, rest of Asia Pacific), LAMEA (Latin America, Middle East, and Africa)
Key Market Players: Chiesi Farmaceutici S.p.A., AbbVie Inc., Mallinckrodt Pharmaceuticals, Mylan N.V., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Sanofi S.A., Boehringer Ingelheim International GmbH,
Report Aspects
Base year: 2024
Historic year: 2022, 2023,2024
Forecast Period: 2025-2035
Report Page: 293
Dominating Segments
Comprehensive BPD Management Is Evolving with Personalised Care and Innovative Lung-Targeted Therapies
A vital focus within the bronchopulmonary dysplasia market is the effective and ongoing management of the condition. This requires a holistic approach combining pharmacological treatments, nutritional support, respiratory care, and continuous monitoring to support fragile, preterm infants. New and emerging therapies that target lung inflammation and promote healthy lung development are beginning to reshape the treatment landscape. These innovations not only improve care but also offer hope for reducing long-term complications.
Additionally, the growing emphasis on personalised medicine and patient-centred strategies is driving research toward more precise and adaptable treatment plans. By tailoring interventions to each infant's unique needs, healthcare providers can deliver more effective, safer care and improve overall outcomes in BPD management.
Growing Awareness and Advancements in Care Are Fuelling Global Growth in the BPD Treatment Market
The global bronchopulmonary dysplasia market is steadily expanding as healthcare systems place greater emphasis on improving outcomes for premature infants. Driven by advances in neonatal care and respiratory therapies, treatment options such as surfactants, bronchodilators, and anti-inflammatory medications are becoming more widely adopted in clinical practice.
In 2025, the global BPD market was valued at approximately $1.39 billion, and it is projected to reach $2.86 billion by 2035, growing at a compound annual growth rate of about 7.5% This upward trend is largely supported by increased awareness among healthcare providers, earlier diagnoses, and a growing focus on comprehensive, individualised care.
As understanding of BPD continues to evolve, so does the potential to improve survival rates and long-term quality of life for affected infants, making this a critical and promising area of growth within the paediatric healthcare landscape.
Key Takeaways
- In terms of revenue, the market is valued at $1.39 billion in 2025,
- It is projected to reach $2.86 billion by 2035.
- North America holds the largest share of the Bronchopulmonary Dysplasia market.
- - Hospitals dominate the market, accounting for about 60% of the market share, followed by Clinics 30% and Others 10%. Hospitals are expected to continue leading, driven by advanced care units and specialised pediatric departments.
- The -Clinic- sub-segment is projected to grow at the fastest rate during the forecast period, driven by increasing outpatient care options for chronic conditions like Bronchopulmonary Dysplasia.
- Leading bronchopulmonary dysplasia companies such as CHIESI Farmaceutici S.p.A., Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others are developing novel bronchopulmonary dysplasia drugs that can be available in the bronchopulmonary dysplasia market in the upcoming years.
Regional Insights
North America Leads the BPD Market with Strong Infrastructure and High Demand for Neonatal Care Solutions
Currently, North America holds the largest share of the global bronchopulmonary dysplasia market, overall, 40% of the total market size. This leadership is fuelled by the region-s advanced healthcare infrastructure, higher healthcare spending, and the strong presence of leading pharmaceutical and medical device companies. And the United States plays an important role in this dominance; it focuses only on the bronchopulmonary dysplasia market. other the growing number of preterm births in the region continues to drive demand for effective therapies, reinforcing North America-s position at the forefront of the BPD treatment landscape.
Europe Strengthens Its Role in the BPD Market with Advancements in Neonatal Care and Early Intervention
Europe plays a specific role in the bronchopulmonary dysplasia market, with countries like Germany, France, and the United Kingdom leading the way. These nations benefit from strong health care systems and a dedicated focus on neonatal care, allowing for good management of conditions like BPD. The government also supports and backs initiatives, early diagnosis programs, and strong awareness campaigns have played a key role in improving care for premature infants. Additionally, the region is home to several major industry players and research institutions actively developing new treatment options for BPD. Because the health care system across Europe continues to prioritise early intervention and innovation, the region is poised to see continuous growth in BPD management and treatment solutions.
Asia Pacific Drives BPD Market Growth with Rising Birth Rates and Strengthening Neonatal Healthcare Systems
The Asia Pacific region is witnessing rapid growth in the BPD market, driven by rising preterm births, expanding neonatal care, and strong government support. Countries like China, India, and Japan are leading efforts to improve awareness, early diagnosis, and maternal-child health across the region.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
North America holds the largest market share, accounting for 40% of the global total. This dominance is driven by advanced healthcare infrastructure, high healthcare spending, a strong presence of leading pharmaceutical and medical device companies, and a significant focus on neonatal care in the United States.
Key growth drivers include the rising global incidence of preterm births, continuous advancements in neonatal care technologies (such as sophisticated respiratory support systems), and increasing awareness among healthcare providers and parents leading to earlier interventions.
Hospitals currently dominate the market, accounting for approximately 60% of the total share. This leadership is attributed to the presence of advanced neonatal intensive care units (NICUs) and specialized pediatric departments. However, the "Clinic" sub-segment is projected to be the fastest-growing due to the rise in outpatient care options.
The market faces several hurdles, including a lack of currently approved specific therapies, a high number of undiagnosed cases due to limited awareness in certain regions, and inconsistent diagnostic criteria across clinical studies, which creates uncertainty in market forecasting.
In December 2024, Oak Hill Bio initiated a clinical trial for OHB-607, a new investigational drug. Additionally, in April 2021, the FDA approved Airway Therapeutics’ IND application for AT-100, a preventive treatment option for BPD in vulnerable newborns.
Researchers are increasingly focusing on tailoring BPD treatments to individual genetic profiles. This shift toward personalized medicine allows for targeted therapies that improve patient outcomes while reducing potential side effects, making neonatal care safer and more effective.
The Asia Pacific region is witnessing rapid growth, led by countries such as China, India, and Japan. This is fueled by rising birth rates, expanding neonatal healthcare systems, and increasing government support for maternal and child health programs.
AI and machine learning tools are becoming vital for early diagnosis and the development of optimized treatment plans. These technologies help clinicians catch BPD signs faster and analyze complex data to improve long-term results for preterm infants.
Prominent market players include Chiesi Farmaceutici S.p.A., AbbVie Inc., Mallinckrodt Pharmaceuticals, AstraZeneca plc, Pfizer Inc., and GlaxoSmithKline plc. Other emerging companies developing novel drugs include Oak Hill Bio, Airway Therapeutics, Windtree Therapeutics, and Trimunocor.
